Location of Repository

Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.

By Patrice Chevallier, Richard M Szydlo, Didier Blaise, Reza Tabrizi, Mauricette Michallet, Madalina Uzunov, Nathalie Fegueux, François Guilhot, Simona Lapusan, Nicole Gratecos, Jean-Yves Cahn, Gerard Socié, Ibrahim Yakoub-Agha, Anne Huynh, Sylvie Francois, Jacques-Olivier Bay, Sébastien Maury, Agnes Buzyn, Nathalie Contentin and Mohamad Mohty

Abstract

International audienceThis retrospective multicenter report assessed the outcome of 600 patients with hematologic diseases older than 60 years who received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT), with the specific aim to compare outcomes of patients between 60 and 65 years old (N = 493) with those older than 65 years (N = 107). Except for donor age, there were no significant differences between the groups regarding patients, diseases, and allo-HSCT characteristics. At time of RIC allo-HSCT, 276 patients (46%) were in complete remission. With a median follow-up of 22.8 and 23.7 months in the younger and the older groups, respectively, 2-year relapse, nonrelapse mortality, disease-free survival, and overall survival rates were similar in both groups (29.6% vs. 20.4%; 29.9% vs. 34.6%; 40.6% vs. 46.7%; 49.2% vs. 50.2%, respectively; P = NS for all comparisons). In a Cox multivariate analysis, after adjustment for disease and transplant factors, age per se was not an adverse factor for survival (relative risk = 1.08; 95% confidence interval, 0.81-1.44, P = .62). We conclude that in selected patients, RIC allo-HSCT could be offered to patients over 65 years old

Topics: MESH : Age Factors, MESH : Aged, MESH : Retrospective Studies, MESH : Risk Factors, MESH : Survival Rate, MESH : Tissue Donors, MESH : Transplantation Conditioning, MESH : Transplantation, Homologous, MESH : Disease-Free Survival, MESH : Female, MESH : Follow-Up Studies, MESH : Hematologic Neoplasms, MESH : Hematopoietic Stem Cell Transplantation, MESH : Humans, MESH : Male, MESH : Middle Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Publisher: Elsevier
Year: 2012
DOI identifier: 10.1016/j.bbmt.2011.07.013
OAI identifier: oai:HAL:hal-00849660v1
Provided by: Hal-Diderot
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://hal.archives-ouvertes.... (external link)
  • https://hal.archives-ouvertes.... (external link)
  • https://hal.archives-ouvertes.... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.